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6/j.bHerpes virus (cytometalovirus [CMV], herpes simplex virus, varicella zoster virus) and invasive fungal infec-
tions continue to cause significant morbidity and mortality in allogeneic hematopoietic cell transplant (HCT)
recipients despite the availability of effective therapies. In this study, we developed an Internet-based survey,
which was distributed to all hematopoietic cell transplant centers participating in the Center for International
Blood and Marrow Transplant Research (CIBMTR) program, to gather information on strategies utilized for
the prevention of disease caused by herpes viruses and fungal infections between 1999 and 2003. The survey
response rate was 72%, representing 175 programs from 32 countries. Generally, reported center strategies
were in accordwith the Center for Disease Control and Prevention guidelines published in 2000, with 81% of
programs using low-dose acyclovir prophylaxis for herpes simplex virus seropositive patients, 99% of pro-
grams reporting use of a CMV prevention strategy during the first 100 days posttransplant for all patients
at risk of CMV disease, and 90% of programs using antifungal prophylaxis. Seventy percent of programs re-
ported routine use of a CMV prevention strategy in high-risk patients after day 100. The greatest departure
from published guidelines was the use of acyclovir prophylaxis for varicella zoster virus seropositive recip-
ients in 75% of programs. There were very few reported changes within centers in practices over the study
time period. Significant regional variations were found with regard to surveillance procedures and treatment
durations. There were no significant differences in treatment practices by center size and very few differ-
ences found between those centers that reported treating primarily pediatric patients versus primarily adult
patients. In summary, our survey demonstrates overall agreement with published guidelines for the preven-
tion of disease because of herpesviruses and fungal infections with significant regional differences found in
duration of antiviral prophylaxis, duration of preemptive therapy, and duration and dosing of antifungal pro-
phylaxis. Center size and age of primary patient population were not associated with many reported differ-
ences in strategies.
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Cytomegalovirus (CMV) infection continues to be
a major cause of morbidity and mortality in recipients
of allogeneic hematopoietic cell transplants (HCTs)
despite the development of effective antiviral therapies
and the advancement of testing modalities for early di-
agnosis [1]. Historically, CMV reactivation occurred
in 60% to 80% of seropositive patients with approxi-
mately one-third of these patients going on to develop
symptomatic CMV disease [2]. The use of CMV pre-
vention strategies with either universal prophylaxis or
preemptive therapy for high-risk patients, has signifi-
cantly decreased the incidence of CMV disease in the
first 100 days after transplantation. Concurrent with
the reduction of early CMV disease, there has been
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ease, posing a further challenge in the coordination of
care for these patients [3,4].
The epidemiology of invasive fungal infections has
also changed significantly in the past 20 years. Before
the widespread adoption of effective antifungal pro-
phylaxis, Candidal infections were the most common
invasive fungal infections in the first 100 days after
transplant and carried significant morbidity and
mortality [5]. Currently, invasive fungal infections
occur in\5% of patients, with molds comprising the
majority of cases [6].
In 2000, the Center for Disease and Prevention
(CDC), the Infectious Disease Society of America,
and the American Society of Blood and Bone Marrow
Transplantation published evidence-based guidelines
for the prevention of opportunistic infections among
HCT recipients [7]. Since then, data describing cur-
rent practices in the surveillance, prophylaxis, and
treatment of CMVhave been limited to individual cen-
ters or countries [8,9]. To more fully understand
current prevention practices, we developed a Web-
based survey to elicit information on center-specific
strategies for the prevention of CMV disease, both in
the early and late posttransplant periods, fungal dis-
ease, and other herpes viruses, such as herpes simplex
virus (HSV) and varicella zoster virus (VZV). This sur-
vey was distributed to all HCT centers participating in
the Center for International Blood and Marrow
Transplant Research (CIBMTR) program, allowing
for comparison of strategies regionally, as well as by
program size, and for adult versus pediatric programs.
Additionally, the time period studied (1999-2003) per-
mitted a comparison of practices immediately prior to
the availability of evidence-based guidelines to those
after the guidelines were published.Figure 1. Flow of survey topics regarding CMV disease prevention after HCT
globulin; GVHD, graft-versus-host disease.MATERIALS AND METHODS
A Web-based survey was designed using Survey
Monkey (http://www.surveymonkey.com) to investi-
gate center-specific practices used to prevent HSV,
VZV, CMV, and fungal diseases in allogeneic trans-
plant recipients during the time period of 1999 to
2003. An e-mail invitation to participate in the survey
was distributed to all program directors at CIBMTR-
affiliatedHCT centers inMay 2006. To optimize early
survey return rates we offered 4 prizes: the recipients
were randomly selected from the centers that returned
the survey within the specified time period.
The survey consisted of 8 questions, many of
which contained several sublevels (Appendix A). In
general, participants were instructed to select the
response that best described their center’s primary
prevention strategies—those strategies used in the
majority of their patients—and indicate if these
changed during the time period 1999-2003. Question
1 inquired about the centers’ strategies for VZV and
HSV prevention in seropositive patients. They were
specifically asked about the use of low-dose acyclovir
(defined here as#5 mg/kg every 8 hours), valacyclovir
(500 mg twice daily), or famciclovir (500 mg twice
daily), and the duration of treatment if used. Question
2 evaluated the use of high-dose acyclovir (defined
here as $800 mg 4–5 times daily) and valacyclovir
(6–8 g daily) as prophylaxis for CMV reactivation.
Questions 3–5 explored the use of ganciclovir- or
foscarnet-based strategies for prevention of CMV re-
activation prior to and after day 100, as demonstrated
in Figure 1. Other topics of interest included the use of
CMV seronegative or leukoreduced blood products
and the use of adoptive cellular immunotherapy. Fi-
nally, participants were asked to describe their center’s. CMV, cytomegalovirus; PET, preemptive therapy; ATG, antithymocyte
666 Biol Blood Marrow Transplant 17:664-673, 2011M. Pollack et al.practices regarding the use of antifungal prophylaxis,
the timing of initiation, the duration of use, and the
preferred drug and dosage. Space was provided at the
end of the survey for qualifying statements. Informa-
tion regarding number of transplants performed by
each center annually was obtained later through direct
e-mail inquiries. The protocol was submitted to the in-
stitutional review board (IRB) at the Fred Hutchinson
Cancer Research Institute and received a designation
of ‘‘Not Human Subjects Research.’’
For each topic, the survey data were tabulated and
analyzed to compare differences in practices based on
geographic region, center size, and primary population
treated (adult, pediatric, or both). As some of the geo-
graphic regions had very few participating centers, sev-
eral regions were grouped together to facilitate
statistical comparisons. Similarly, although we col-
lected more detailed data on program size, the data
were ultimately analyzed in 2 groups: those programs
that performed #50 allogeneic stem cell transplants
annually and those that performed .50 per year.
A chi-square test or Fisher’s Exact test were used to
calculate P-values for the comparisons. Two-sided
P-values of\.05 are considered significant.RESULTS
Participating Centers
The surveyWeb linkwas sent to the programdirec-
tors of 244 CIBMTR centers. Responses were received
from 175 centers (72%) in 32 countries. The 69
programs that did not respond were from a wide
distribution of geographic locations and, we assume,
were otherwise similar to the programs that partici-
pated. There was wide variation in participant center
size with 62% performing 50 or fewer allogeneic
transplants annually and 12% performing more thanTable 1. Regional Comparison of Patient Age Groups and Cent
Responses (72%), from 32 Countries*)
Reg
Patient characteristics
Total %
(n 5 175)
U.S./CAN %
(n 5 97)
Europe %
(n 5 40)
Primarily adult 46.3 47.4 50.0
Primarily Pediatric 21.1 23.7 17.5
Both adult and pediatric 32.6 28.9 32.5
No of allogeneic transplants/year†
<25 33.7 29.9 22.5
26-50 28.0 30.9 32.5
51-100 20.0 20.6 32.5
101-200 9.7 8.2 10.0
>200 2.3 4.1 0.0
Missing data 6.3 6.2 2.5
*Countries represented by region (number of responding programs): U.S./Can
dom (7), Spain (5), Belgium (3), Sweden (2), Finland (2), Italy (2), Switzerland (1
Australia/NZ—Australia (10), New Zealand (3); Latin America-Brazil (3), Arge
Iran (1), Pakistan (1); Asia—India (2), China, Hong Kong (1), Japan (1), Taiwan
†Data regarding center size were obtained via direct correspondence after su100 (Table 1). Additionally, 46% of centers treated pri-
marily adult patients, whereas 21%were primarily pedi-
atric centers allowing for comparison of practices
between adult and pediatric patients. The survey was
completed by a variety of HCT professionals: 136
physicians, of which 54 were the directors of the HCT
programs at their institution; 11 nurses or nurse practi-
tioners; and28 research coordinators anddatamanagers.HSV and VZV Prophylaxis
Eighty-one percent of programs reported using
low-dose acyclovir, valacyclovir, or famciclovir for pro-
phylaxis in either VZV seropositive (VZV1) or VZV
seronegative/HSV seropositive patients (VZV2/
HSV1) (Table S1). This proportion increases to
94.2%when those programs using high-dose acyclovir
or ganciclovir for CMV prophylaxis were included.
Nevertheless, there were still 10 programs that did
not use any prophylaxis for VZV1 or VZV2/HSV1
patients. Of the 34 programs (23.9%) that did not re-
port using low-dose acyclovir prophylaxis for VZV1
patients, 8 were using high-dose acyclovir and 7 were
using ganciclovir prophylaxis forCMVseropositive pa-
tients. American/Canadian and Latin-American pro-
grams reported using low dose acyclovir in 88.7% and
91.7% of respondents, respectively. This was signifi-
cantly different from other regions, where low-dose
acyclovir use was reported between 53.8% and 72.5%
of respondents (P 5 .006) (Table S1). There were no
significant differences in use of low-dose acyclovir
based on pediatric versus adult patient populations or
program size (Table S2). There were also no changes
in treatment strategies reported in either VZV1 or
VZV2/HSV1 patients over the time period studied.
Among those centers that used low-dose acyclovir
prophylaxis, there was remarkable regional variation in
treatment duration (P 5 .008) (Table 2 and S1). Forer Size of Survey Participants (244 Centers Contacted, 175
ional Location of Survey Participants
Aust/NZ %
(n 5 13)
L. America %
(n 5 12)
Asia %
(n 5 6)
Middle East %
(n 5 4)
Africa %
(n 5 3)
61.5 33.3 16.7 25.0 33.3
38.5 8.3 16.7 0.0 0.0
0.0 58.3 66.7 75.0 66.7
61.5 75.0 33.3 0.0 66.7
23.1 16.7 0.0 25.0 0.0
7.7 0.0 16.7 0.0 0.0
0.0 0.0 33.3 75.0 0.0
0.0 0.0 0.0 0.0 0.0
7.7 8.3 16.7 0.0 33.3
—United States (90), Canada (7); Europe—Germany (13), United King-
), Norway (1), Denmark (1), Poland (1), Portugal (1), Czech Republic (1);
ntina (3), Uruguay (3), Venezuela (2), Mexico (1); Middle East—Israel (2),
(1), Korea (1); Africa—South Africa (3).
rvey was completed.
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treat for longer duration with 40.2% of programs
treating for at least 6 months and 17.5% of programs
treating for at least 1 year. Alternately, excluding pro-
grams that were using high dose acyclovir for CMV
prophylaxis, 21.8% of American centers did not use
any prophylaxis for VZV prevention. A higher per-
centage of European centers used low-dose acyclovir
in VZV1 patients, but for shorter durations with the
majority treating for less than 4 months. There were
no significant differences in the duration of low-dose
acyclovir prophylaxis for VZV1 patients in pediatric
versus adult patients or by program size (Table S2).
For VZV2/HSV1 patients, low-dose acyclovir
prophylaxis was used at more centers, with a trend to-
ward shorter treatment durations in most regions.
American/Canadian, and Latin American programs
treated for longer durations than other regions, with
35.6% and 20.0% of programs respectively treating
for as long as 12 months (Table S1). Only 1 program
outside of these regions treated for as long (P 5 .017).
Most programs treated only until engraftment or for
3 to 4 months after transplantation. Again, there
were no significant differences in practices among
programs that primarily treated pediatric versus adult
patients or by program size (Table S2).CMV Prevention in Seropositive Patients
High-dose acyclovir or valacyclovir prophylaxis
Fifty-five programs (31.4%) reported using high-
dose acyclovir or valacyclovir for prevention of
CMV disease in at-risk patients during the study
time period (Table S1). European programs used this
strategy in 47.5% of programs, significantly more
than American/Canadian programs (23.7%, P 5 .008).
However, when comparing responses among all re-
gions, the differences are not statistically significant
(P5 .063). This strategy was more commonly utilized
in centers that treated primarily pediatric patients
(54.1%) versus those that treated primarily adult pa-
tients (22.2%) (P 5 .002) (Table S2). There were noTable 2. Duration of Low-Dose Acyclovir Prophylaxis* for VZV and
Do Not Treat† 1 Month
VZV+ VZV2/HSV+ VZV+ VZV2/HSV+
U.S./CAN % (n 5 97) 26.8 7.2 6.2 25.8
Europe % (n 5 40) 10.0 0.0 20.0 30.0
Aus/NZ % (n 5 13) 23.1 7.7 15.4 30.8
Latin America % (n 5 12) 25.0 0.0 25.0 33.3
Asia % (n 5 6) 16.7 16.7 33.3 50.0
Middle East % (n 5 4) 25.0 25.0 0.0 0.0
South Africa % (n 5 3) 33.3 33.3 0.0 0.0
HSV indicates herpes simplex virus; VZV, varicella zoster virus.
*Includes acyclovir #5 mg/kg every 8 hours, valacyclovir 500 mg twice daily, o
†Excludes those programs that use high-dose acyclovir prophylaxis for cytom
‡Treatment duration equal to 6 months or until discontinuation of immunosusignificant differences noted based on the size of the
transplant center.
There were notable variations in duration of treat-
ment among those centers using high-dose acyclovir
or valacyclovir with 32.7% of programs treating for 1
month or until engraftment, 40% treating for 3 to 4
months, and23.6%treating for at least 6months oruntil
immune reconstitution. Regional differences were
noted with a majority (57.9%) of European programs
treating for 3 to 4 months, American/Canadian pro-
grams treating only until engraftment 40.9% of the
time, and extending treatment for at least 12 months
27.3% of the time, and other regions treating for 3 to
4 months a majority of the time (P 5 .005) (Table S1).
Therewere no significant differences in treatment dura-
tion by age of patient population or program size (Table
S2). Fifty (92%) of the programs reported using the
same practices consistently over the study time period.Ganciclovir or foscarnet prophylaxis
By 2003, 167 of 175 respondents reported using
a ganciclovir-based CMV prevention strategy, either
prophylaxis or preemptive therapy, and 1 program
used a foscarnet-based strategy. Forty-eight (27%)
centers reported using ganciclovir (n 5 47) or foscar-
net (n 5 1)-based prophylactic therapy in at least
some allogeneic transplant recipients between 1999
and 2003 (Table S1). Although there was no significant
difference in the use of this strategy by region, pediat-
ric versus adult centers or center size, there was a sug-
gestion of higher use of this strategy in centers in
Australia/New Zealand. Seven of 13 programs
(53.9%) in Australia/New Zealand used ganciclovir
prophylaxis for some portion of the study period com-
pared with 21.6% of United States/Canadian and 25%
of European programs. However, by 2003, only 38.5%
of centers in Australia and New Zealand were still
using this strategy. Seventy percent of centers that
used ganciclovir prophylaxis reported consistent use
of prophylaxis for each year of the study period, with
the remainder switching to a preemptive strategy
between 2000 and 2002.HSV by Region
3-4 Months 6 Months ‡ $12 Months
VZV+ VZV2/HSV+ VZV+ VZV2/HSV+ VZV+ VZV2/HSV+
11.3 20.6 24.7 23.7 17.5 13.4
32.5 32.5 3.1 2.1 0.0 0.0
15.4 23.1 1.0 1.0 1.0 1.0
25.0 33.3 1.0 1.0 1.0 1.0
16.7 16.7 1.0 0.0 0.0 0.0
50.0 50.0 0.0 0.0 0.0 0.0
33.3 33.3 0.0 0.0 0.0 0.0
r famciclovir 500 mg twice daily.
egalovirus (CMV) seropositive patients.
ppression.
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Two-thirds of centers using ganciclovir-based pro-
phylaxis for prevention of CMV initiated treatment at
the time of engraftment (n 5 26), whereas a one-third
started prophylaxis pretransplant (n5 13), many com-
menting that therapy was interrupted on day 0 and
reinitiated after engraftment. One center started
pretransplant if the transplant recipient was CMV
seropositive but waited until engraftment if only the
donor was CMV seropositive. These findings were
consistent across regions, patient populations, and
center sizes. All practices were stable over the time
period the center was using a prophylactic strategy.
Ganciclovir prophylaxis duration
Thirty-seven (77.2%) of the 48 programs using
ganciclovir prophylaxis, continued treatment for #3
months, whereas 18.8% of programs treated for be-
tween 3 and 6months and 6.3% treated for.6months
(Table S1). There were no significant differences
noted by region, pediatric versus adult patients, or cen-
ter size. ‘‘Other’’ responses were noted in only 2 pro-
grams included treating until CMV specific immune
response was detected and treating until CD4 count
was .200. Again, all practices were stable over each
year the center was using a prophylactic strategy.
Ganciclovir or foscarnet preemptive therapy
Table 3 compares the use of prophylactic versus pre-
emptive therapy in all participating centers bypatient risk
group in 2003. During the previous study years 1999-
2002, 10 programs switched from a prophylactic to a
preemptive treatment strategy. Sixty-eight percent of
programs endorsed using a strategy of preemptive ther-
apy alone, comparedwith only 5.1%whoendorsedusing
ganciclovir-based prophylaxis alone. Several programs
(22.3%) reported using both strategies in the same time
period, possibly indicating that the center policies
allowed physicians to choose which strategy was used.
For HLA identical siblings, preemptive therapy
alone was used in 77.7% of centers, whereas prophy-
laxis alone was used in 4.6% and physician preference
in 11.4%. In transplants involving unrelated donors or
partially HLA-mismatched related donors, preemp-
tive therapy alone was used in 65.1% of programs, pro-
phylaxis alone in 5.7%, and physician preference in
16.0% of programs. The survey asked respondents
whether a particular strategy was used for a givenTable 3. CMV Prevention: Ganciclovir Prophylaxis versus Preempt
n 5 175 Programs
Ganciclovir Prophyl
Alone (%)
HLA identical siblings 4.6
Unrelated donors or partially HLA-mismatched related 5.7
Recipients of nonmyeloablative conditioning 4.0
CMV indicates cytomegalovirus; n, number.risk group, without asking whether that center actually
performed transplantation in that risk group during
the time period studied. Thus, if the strategy was not
affirmed in the risk group it could either be because
they did not use that strategy in that group or because
they did not perform transplantations in that particular
risk group. Therefore, we only had an approximate de-
nominator and the proportions do not all add up to
100%. A similar pattern was seen for recipients of non-
myeloablative conditioning where 69.7% of programs
used preemptive therapy alone, 4.0% used prophylaxis
alone, and 8.6% used physician preference. The survey
was not designed to obtain reliable data on this issue
for T cell-depleted grafts and haploidentical donors.
There were no significant regional differences
in the use of preemptive therapy in transplants
involving HLA identical siblings, unrelated or HLA-
mismatched related donors, or recipients of nonmye-
loablative conditioning. There were also no significant
differences in the proportion of programs using
preemptive therapy among pediatric and adult centers
or by center size (Tables S1 and S2).
Among those programs using a strategy of pre-
emptive therapy, 62.0% of programs performed sur-
veillance on all patients, whereas 36.1% of programs
screened only patients who were seropositive at the
time of their transplant and those seronegative patients
who received a graft from a seropositive donor. Only
1.9% of programs performed surveillance exclusively
on patients who were seropositive at the time of their
transplantation and at highest risk of reactivation.
Again, there were significant regional differences in
the patient populations selected for routine surveil-
lance (Table S1). European and Latin American
programs tended to subject all transplant recipients
to surveillance, regardless of CMV status (81.6% and
90.0%, respectively), whereas in American/Canadian
and Australian/New Zealand programs, seronegative
recipients from seronegative donors (D2/R2) were
less likely to be screened (51.6% and 55.6%, respec-
tively) (P \ .001). There were no differences in
patients selected for surveillance based on patient
population or center size (Table S2).
Method of CMV surveillance
A variety of tests were used to detect subclinical
CMV among those programs using a preemptive strat-
egy. Forty-six percent of programs used CMV antigen
(pp65) testing, whereas 28.5% used a plasma CMVive Therapy by Risk Group in 2003
axis Preemptive Therapy
Alone (%)
Physician
Preference (%)
Missing
Information (%)
77.7 11.4 6.3
65.1 16.0 13.1
69.7 8.6 17.7
Biol Blood Marrow Transplant 17:664-673, 2011 669Comparison of Strategies to Prevent Herpesvirus in HCT RecipientsDNAPCR test and 22.2% used a whole blood or white
blood cell-based CMV DNA PCR test (Supplemental
data). Two percent of programs used CMV shell vial
testing. These trends were stable across regions, pa-
tient population, and center size. Eighty-seven percent
of programs reported using the same detectionmethod
over the entire study period. Of the 13 programs that
changed the testing method, all but 1 program
switched from a pp65 antigen test to a PCR test.
Frequency of surveillance
The great majority of programs (91.1%) per-
formed CMV surveillance testing at least weekly dur-
ing the first 100 days posttransplant in the years they
were utilizing a strategy of preemptive therapy. Eight
programs (5.1%) performed surveillance testing twice
weekly and 7 programs employed a deescalating strat-
egy of surveillance testing weekly initially and then less
frequently over time. The strategies were stable over
the time period that the center was using preemptive
therapy and there were no significant differences based
on region, patient population, or center size.
Duration of treatment
There was considerable variation in the duration of
treatment once CMV was detected by surveillance
(Figure 2), with the majority of programs treated for
at least 2 to 3 weeks and clearance of CMVDNAor an-
tigen from blood. There were no significant differ-
ences by region, patient population, or center size.
Prevention of Late CMV Disease
Approximately 60% of respondents (108 centers)
reported using either a prophylactic or preemptive
strategy with high-risk transplant recipients after day
100 (Figure 3). Ninety-seven centers (55.4%) used
a strategy of virologic surveillance with preemptiveFigure 2. Duration of preemptive therapy for CMV when detected by
surveillance testing (n 5 158). *Clearance of CMV (pp65) antigenemia
or CMV DNAemia. **Day 100 posttransplant.therapy. The majority of these programs (55.0%) per-
formed surveillance testing twice monthly. Thirty-
four centers (27.9%) tested at least weekly, whereas
22 (18.0%) centers performed testing on a more
variable schedule. Among the centers utilizing a
prophylactic approach, 4 programs treated with
high-dose valacyclovir, 2 used valganciclovir, and 1
used oral ganciclovir.
Sixty-seven programs (38.3%) did not use either
surveillance with preemptive therapy or prophylaxis
to prevent CMV disease after day 100 during the study
period. There were no significant differences noted
based on region, patient population or center size
(Tables S1 and S2).
Use of CMV Negative and/or Leukoreduced
Blood Products
Most programs were using some strategy to reduce
CMV transmission via blood products during the
study period (Figure 4). Sixty programs (34.3%) used
both CMV seronegative blood products and leukore-
duction. Forty-eight programs (27.4%) used leukore-
duced blood products only. Thirty-four programs
(19.4%) used CMV seronegative blood products pref-
erentially, but used leukoreduced blood products when
CMV seronegative products were not available. A
much smaller number of centers (5.7%) used CMV se-
ronegative blood only, and 2.3% used 1 or the other
with no preference. Centers that treat primarily adults
were more likely to use both CMV negative blood
products and leukoreduction as compared to centers
that treated primarily pediatric patients and centers
that treated both (46.2% versus 28.6% and 28.6%,
respectively, P 5 .016) (Table S1). Twelve centers
(6.9%) did not have any program strategy for using
CMV seronegative blood products or leukoreduction
in allogeneic transplant recipients.Figure 3. CMV prevention strategy after day 100 posttransplant
(n 5 175).
Figure 4. Strategies for prevention of CMV transmission via blood
products (n5 175). CMV(2) indicates blood products from CMV sero-
negative donors.
Figure 5. Antifungal prophylaxis utilization, primary drug, and dose
(n 5 175). *Other antifungal prophylaxis regimens included: amphoter-
icin B doses ranging from 0.1-0.6 mg/kg/day, liposomal amphotericin
B 3 mg/kg twice weekly, voriconazole 200-400 mg/day, caspofungin 50
mg/m2/day, or a sequence of 2 different agents. **Or the weight based
equivalent of 4-6 mg/kg/day.
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Only 7 centers (4.0%) reported using adoptive cel-
lular immunotherapy in allogeneic transplant recipi-
ents during the years 1999 to 2003. One program
utilized adoptive cellular immunotherapy as prophy-
laxis, 2 programs as preemptive therapy, and 4
programs utilized it only after initial failure of
pharmacologic preemptive therapy.
Antifungal Prophylaxis
Ninety percent of program respondents reported
using systemic antifungal prophylaxis in allogeneic
transplant recipients (Table S1). Although there were
no differences in reported antifungal use by center
size or patient population, there were significant re-
gional variations. Of the 19 programs that did not
use antifungal prophylaxis, 9 were in European coun-
tries, 2 were in South Africa, and 3 were in Canada,
representing 22.5%, 33.3%, and 42.8% of the region’s
or country’s programs, respectively. In comparison,
only 3% of programs in the United States, and no
programs in Australia, New Zealand, or Latin America
reported not using antifungal prophylaxis during the
study period (Table S1).
The majority of programs (69.1%) chose flucona-
zole as their primary agent for prophylaxis, with 36%
using a dose of 400 mg/day or the weight-based equiv-
alent of 4–6 mg/kg/day, 13.7% using 200 mg/day, and
19.4% reporting either lower doses or a dosing range
(Figure 5). Approximately 10% of programs used itra-
conazole as their primary agent for prophylaxis and an-
other 10% reported the use of other antifungal agents.
Only 7 programs (4.4%) reported a change in theprimary drug used for antifungal prophylaxis between
1999 and 2003, all switching from fluconazole to
itraconazole.
Antifungal prophylaxis was initiated at the time of
the pretransplant conditioning regimen in 63% of cen-
ters, whereas 27% of centers started antifungal pro-
phylaxis at the time of transplant: day 0 (61 day)
(Table S1). Antifungal prophylaxis was continued until
engraftment in 23% of programs. Forty-eight percent
of centers reported use of antifungal prophylaxis until
days 75 to 100 posttransplant, and 29% reported some
other duration. There were no significant differences
in duration of treatment by region, center size, or pa-
tient population (Tables S1 and S2). Of the centers
that used antifungal prophylaxis, 98% reported consis-
tent use of their chosen duration of treatment between
1999 and 2003. Two programs started using antifungal
prophylaxis in 2001 and 2003, respectively, and 1 pro-
gram stopped using antifungal prophylaxis after 2002.DISCUSSION
The development of sensitive diagnostic testing
and effective antiviral and antifungal therapies has
done much to decrease the morbidity and mortality
due to CMV, invasive fungal infections, and other her-
pes viruses after HCT. With the publication of
evidence-based guidelines by the CDC in 2000, physi-
cians and transplant centers were provided with
detailed recommendations for the prevention and
treatment of opportunistic infections in HCT. How-
ever, to our knowledge, there have been no studies in-
vestigating the adoption of these recommendations
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a unique opportunity to perform such a study using
a simple, Web-based survey tool. With a response
rate of 72%, representing 175 programs in 32 different
countries, we were able to obtain a detailed view of the
strategies utilized both before and after publication of
these guidelines.
In accordance with the CDC recommendations,
approximately one-quarter of programs did not use
long term low-dose suppressive acyclovir in VZV sero-
positive patients (DIII) [7]. However, three-quarters of
programs departed from the recommendation by treat-
ing for varying durations, with approximately one-fifth
of the programs treating for the first year after trans-
plantation. We speculate that this practice was influ-
enced by a randomized, placebo-controlled trial of
long term acyclovir for prevention of VZV disease,
which had been completed and presented in abstract
form at international meetings, but was not published
at the time the guidelines were written. In the most
recent guidelines this has been upgraded to a BI level
recommendation [10].We observed statistically signif-
icant regional variation in the treatment strategy
utilized for VZV1/HSV2 patients. For example, in
Europe, 90% of centers treated for some duration of
time, varying from1 to 4months, but no centers treated
for as long as 1 year. In contrast, one-third of North
American centers did not offer any prophylaxis and
one-third treated for the entire first year (Table S1).
Again, this division likely reflects evidence-based
transitions of practice prior to their inclusion in the
published guidelines.
A majority of centers utilized low-dose acyclovir
prophylaxis to HSV1 patients after HCT, which is
consistent with CDC recommendations (AI). How-
ever, given the proven efficacy, excellent safety pro-
file, and the low cost of acyclovir prophylaxis, it
was surprising that there were 10 programs that
did not appear to be using any strategy for HSV dis-
ease prevention. There was significant regional vari-
ation in the duration of acyclovir prophylaxis. The
CDC guidelines recommend continuation of acyclo-
vir until engraftment or resolution of mucositis,
whichever is longer (BIII), while recommending
against treatment for longer than 1 month (DIII)
[7]. In our study we found that a similar number of
programs were in accord with this recommendation
as departed from it by treating HSV1/VZV2 patients
for much longer durations. Approximately one-
quarter of programs treated for at least 6 months or
discontinuation of immunosuppression, and about
one-eighth treated for 1 year. This practice is encour-
aged by evidence that long-term suppressive therapy
with low-dose acyclovir (800 mg twice daily or 500
mg twice daily of valacyclovir) reduces the incidence
of HSV disease and the development of acyclovir
resistant HSV [11].All but 2 of the participating programs placed all
patients at risk for posttransplant CMV disease on
a CMV disease prevention program for the first 100
days posttransplant, with high-dose acyclovir, prophy-
lactic ganciclovir, or surveillance with preemptive
therapy (AI). Surveillance with preemptive ganciclovir
or foscarnet therapy was used by 90.8% of centers in at
least some patients, compared to 31.4% of programs
using high-dose acyclovir and 27.6% using ganciclovir
prophylaxis. There were no significant differences in
the use of these strategies across all regions. However,
there was considerable regional variation in the
duration of prophylaxis and the duration of treatment
after detection with surveillance. Approximately one-
quarter of programs indicated that their center used
both a strategy of ganciclovir prophylaxis and surveil-
lance with preemptive therapy during the same time
period. This could be interpreted as a center policy
allowing physicians to choose between 2 equally
recommended strategies. However, it is also possible
that the survey questions weremisinterpreted, a limita-
tion common to all survey studies.
There were no significant differences in treatment
practices by center size as determined by the number of
transplants performed annually, comparing those cen-
ters that perform .50 allogeneic transplants per year
to those that perform\50 per year. Moreover, with
a few exceptions, no differences in practices existed
between those centers that treated primarily pediatric
patients, those that treated primarily adult patients,
and those that treated both. The most interesting
exception was the increased use of high-dose acyclovir
prophylaxis in patients at risk for CMV disease in one-
half of centers that treated primarily pediatric patients
compared with only one-quarter of those that treated
primarily adults and those that treated both. It is pos-
sible that this prophylactic strategy is used less
commonly in centers that treat adults because of the
weight-based dosing of the parenteral acyclovir
formulation, which could be deemed prohibitively
expensive for adult patients at some centers.
Althoughmost programs reported center strategies
that were consistent with the recommendations for
prevention ofCMV reactivation in the first 100 days af-
ter HCT, many fewer programs continue to monitor
for CMV after day 100, with 38% of programs report-
ing that they do not routinely use either prophylaxis or
surveillance with preemptive therapy for high-risk
patients after day 100.However, themost recent guide-
lines have increased the rating to a BII level based on
a nonrandomized study where patients at high risk
for CMV disease continued to undergo surveillance
for 26 weeks after HCT [12,13]. In this study, 27%
of patients required preemptive treatment after day
100; however, there were no cases of CMV disease.
It is likely that an updated query would find a greater
number of programs continuing their CMV
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frequency of surveillance testing observed in this study
is indicative of the paucity of clear evidence to guide
providers in these decisions [10].
All but 12 of the 175 participating programs used
some method of decreasing the risk of CMV transmis-
sion via blood products, an AI level recommendation,
by using either blood products from CMV seronega-
tive donors, leukoreduced blood products, or both.
This survey-based study is, to our knowledge, the
first to compare center-specific practices for the pre-
vention of herpes virus infections after HCT in a large
number of programs from 32 different countries. Be-
cause of the high response rate, and the diversity of
the participating programs, we were also able to
make comparisons by patient age population and by
center size. However, the large number of compari-
sons performed increases the probability of finding
statistically significant differences when there is no
true difference. This statistical problem places a limit
on the inferences that should be made about these, pri-
marily descriptive, data. Another limitation of this
study is that the survey asked the respondents about
the prevention strategies used by their centers a few
years in the past; thus, their answers are potentially
subject to recall bias. Also, although the survey reflects
institutional practices actual adherence to these stated
practices was unknown. As with many survey studies, it
is also possible that, despite careful attention to design
of the questions, misinterpretation by the respondents
could have affected the accuracy of our findings.
Finally, prevention strategies in specific transplant
risk groups could not be performed.
In conclusion, in this large, multinational survey,
center-specific practices regarding prevention and
treatment of herpes virus infections were examined.
Most, but not all, responding centers reported provi-
sion of HSV, VZV, and CMV prevention and treat-
ment regimens prior to the publication of the CDC
guidelines in 2000. Although several programs
reported switching from a CMV antigen-based sur-
veillance method to PCR-based detection, overall,
very few centers reported significant changes in their
prevention and treatment strategies between 1999
and 2003. Additionally, with the exception of increased
use of high-dose acyclovir for CMV prophylaxis at
centers that treated primarily pediatric patients, there
were no differences in center strategies based on pa-
tient age or the number of transplants performed an-
nually. There is an ongoing need for high-quality
clinical studies to clarify many of these questions as
reflected in the significant regional differences ob-
served in the following areas: (1) duration of antiviral
prophylaxis for HSV and VZV seropositive patients,
(2) duration of antiviral prophylaxis for patients
at risk of CMV disease, (3) selection of patients toundergo CMV surveillance testing, (4) duration of
preemptive therapy, and (5) strategies for prevention
of late CMV disease.ACKNOWLEDGMENTS
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